New Radioactive Gel Destroys Deadly Cancer Tumors From Within

Biomedical engineers at Duke University have developed a radioactive gel implant that has demonstrated the ability to eliminate pancreatic tumors in mouse models. This approach targets one of the deadliest forms of cancer, which is frequently resistant to many drugs and often detected too late for traditional interventions.

The treatment utilizes a biocompatible gel composed of elastin-like polypeptides (ELPs). This gel serves as a delivery vehicle for radioactive iodine-131, which is injected directly into the tumor.

Mechanism of Action

The primary function of the ELP gel is to trap the radioactive isotope safely within the cancerous tissue. By confining the radioactive particles, the gel allows for the steady release of beta radiation to destroy cancer cells from the inside.

This localized delivery method ensures that the radiation targets the tumor while avoiding damage to surrounding healthy organs. According to research published in Nature Biomedical Engineering in 2022, this internal radiation strategy allows chemotherapy drugs to function more effectively than when using traditional external radiation beams.

Experimental Results

In pre-clinical trials using mouse models, the radioactive gel was paired with chemotherapy. The results showed that tumors responded to the treatment across all models tested.

The treatment completely eliminated tumors in 80% of mice across multiple model types, including those categorized as the most difficult to treat. This outcome differs from many other mouse trials, where success is often defined simply as the halting of tumor growth.

Clinical Context and Future Outlook

Pancreatic cancer has long been viewed as nearly untouchable by modern therapies due to its aggressive nature and resistance to standard treatments. The Duke University team has described these findings as some of the most exciting developments in decades of research into the disease.

While the results in mouse models are significant, the researchers note that human trials remain a few steps away. The potential application of this strategy may also extend beyond pancreatic cancer to other types of tumors that are traditionally hard to treat.

The study involving the synergy between the biopolymer-bound 131I depot and nanoparticle paclitaxel was detailed by Jeffrey L. Schaal and colleagues in the 2022 publication in Nature Biomedical Engineering.